Share
The latest acquisition is intended to enhance the combined expertise of Alexion and AstraZeneca in genomic therapy. Credit: Tada Images / Shutterstock.com.

Research group Alexion, Rare Disease 听for acquiring and licensing 鈥檚 early-stage gene therapy portfolio for rare diseases.

Alexion will make a payment of $1bn, aside from sales-based royalty payments, to acquire the preclinical gene therapy assets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition also comprises enabling technologies. Alexion will gain access to a number of new adeno-associated virus (AAV) capsids, which are an efficient approach offering therapeutic gene cargos in gene therapies and gene editing processes.

The latest asset acquisition will enhance the combined expertise of Alexion and AstraZeneca in genomic therapy. 

Alexion CEO Marc Dunoyer stated: 鈥淭he announcement represents another major step forward in Alexion and AstraZeneca鈥檚 ambition to be an industry leader in genomic medicine, which has the potential to be transformative and even curative for patients with devastating diseases. 

鈥淲e look forward to continuing our work to develop enhanced platforms and technologies with broad therapeutic applications while integrating best-in-class expertise to accelerate promising therapeutics into the clinic.鈥�

The deal will conclude in the third quarter of 2023.

In 2022, AstraZeneca acquired LogicBio to create novel genetic therapies with enhanced safety and efficacy profiles. 

The company reported total revenue of $11.4bn in the second quarter (Q2) of 2023 compared to $10.77bn in the prior year’s Q2, a 6% rise.

Core earnings per share rose by 25% for the quarter, to $2.15.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by听Cytiva.

Editorial听content is independently produced and follows the听听of journalistic integrity. Topic sponsors are not involved in the creation of听editorial听content.